| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 21, 2005
Accepted on July 26, 2005
Department of Periodontics/Prevention/Geriatrics, School of Dentistry, University of Michigan (A.J.K., J.H., N.S.D., R.S.T., L.K.M.), Department of Periodontology, Faculty of Dentistry, Hacettepe University, Ankara Turkey (B.D., R.M.N.) Oral Health Sciences Ph.D. Program, University of Michigan (K.G.N.), Winship Cancer Institute, Emory University (H.S.), Department of Pathology, Medical School, University of Michigan (L.K.M.)
* To whom correspondence should be addressed. E-mail: mccauley{at}umich.edu.
Parathyroid hormone (PTH) is an anabolic agent used to treat osteoporosis, but its mechanisms of action are unclear. This study elucidated target cells and mechanisms for anabolic actions of PTH in mice during bone growth. Mice with c-fos ablation are osteopetrotic and lack an anabolic response to PTH. In this study there were no alterations in PTH-regulated osteoblast differentiation or proliferation in vitro in cells from c-fos -/- mice compared with +/+, hence the impact of osteoclastic cells was further investigated. A novel transplant model was used to rescue the osteopetrotic defect of c-fos ablation. Vertebral bodies (vossicles) from c-fos -/- and +/+ mice were implanted into athymic hosts and the c-fos -/- osteoclast defect was rescued. PTH treatment to vossicle bearing mice increased BrdU positivity in the bone marrow and increased bone area regardless of the vossicle genotype. To inhibit recruitment of osteoclast precursors to wild-type vossicles, stromal derived factor-1 (SDF-1) signaling was blocked which blunted the PTH anabolic response. Treating mice with osteoprotegerin (OPG) to inhibit osteoclast differentiation also blocked the anabolic action of PTH. In contrast, using c-src mutant mice with a late osteoclast differentiation defect, did not hinder the anabolic action suggesting key target cells reside in the intermediately differentiated osteoclast population in the bone marrow. These results indicate that c-fos in osteoblasts is not critical for PTH action, but that cells of the osteoclast lineage are intermediate targets for the anabolic action of PTH.
This article has been cited by other articles:
 |
|
 |
|
  T. Kawano, N. Troiano, D. J. Adams, J. Jun Wu, B.-h. Sun, and K. Insogna The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice Endocrinology, August 1, 2008; 149(8): 4009 - 4015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Garimella, S. E. Tague, J. Zhang, F. Belibi, N. Nahar, B. H. Sun, K. Insogna, J. Wang, and H. C. Anderson Expression and Synthesis of Bone Morphogenetic Proteins by Osteoclasts: A Possible Path to Anabolic Bone Remodeling J. Histochem. Cytochem., June 1, 2008; 56(6): 569 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Wang, Y. Liu, and D. W. Rowe Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E594 - E603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Karsdal and K. Henriksen Osteoclasts Control Osteoblast Activity IBMS BoneKEy, January 1, 2007; 4(1): 19 - 24. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Strewler The Stem Cell Niche and Bone Metastasis IBMS BoneKEy, May 1, 2006; 3(5): 19 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Ferrari, E. Seeman, and G. J. Strewler Clinical and Basic Research Papers - October 2005 Selections IBMS BoneKEy, November 1, 2005; 2(11): 1 - 6. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
